Advertisement

Topics

FDA Grants Orphan Drug Designation to Sobi’s Treatment for MPS IIIA

09:20 EDT 5 Jul 2017 | Speciality Pharma Journal

STOCKHOLM–(BUSINESS WIRE)–Swedish Orphan Biovitrum AB (publ) (Sobi™) has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the company’s development candidate SOBI003, a chemically modified human recombinant sulfamidase for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A, a rare metabolic disorder. “We are …

Original Article: FDA Grants Orphan Drug Designation to Sobi’s Treatment for MPS IIIA

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Orphan Drug Designation to Sobi’s Treatment for MPS IIIA"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...